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Abstract
Introduction: A subgroup of voltage gated sodium channels including Nav1.8 are exclusively expressed on small
diameter primary afferent neurons and are therefore believed to be integral to the neurotransmission of
nociceptive pain. The present study examined whether local application of A-803467, a selective blocker of the Nav
1.8 sodium channel, can reduce nociceptive transmission from the joint in a rodent model of osteoarthritis (OA).
Methods: OA-like changes were induced in male Wistar rats by an intra-articular injection of 3 mg sodium
monoiodoacetate (MIA). Joint nociception was measured at day 14 by recording electrophysiologically from knee
joint primary afferents in response to non-noxious and noxious rotation of the joint both before and following
close intra-arterial injection of A-803467. The effect of Nav1.8 blockade on joint pain perception and secondary
allodynia were determined in MIA treated animals by hindlimb incapacitance and von Frey hair algesiometry
respectively.
Results: A-803467 significantly reduced the firing rate of joint afferents during noxious rotation of the joint but
had no effect during non-noxious rotation. In the pain studies, peripheral injection of A-803467 into OA knees
attenuated hindlimb incapacitance and secondary allodynia.
Conclusions: These studies show for the first time that the Nav1.8 sodium channel is part of the molecular
machinery involved in mechanotransduction of joint pain. Targeting the Nav1.8 sodium channel on joint
nociceptors could therefore be useful for the treatment of OA pain, avoiding the unwanted side effects of non-
selective nerve blocks.
Introduction
Osteoarthritis (OA) is a musculoskeletal disorder in
which joint degeneration leads to a loss of mobility and
function. OA primarily affects the weight bearing joints
(for example knees, hips) and is typified by synovitis and
degeneration of the articular cartilage and subchondral
bone. The most prominent feature but least understood
aspect of OA is joint pain which typically worsens with
weight bearing and activity. The clinical diagnosis and
treatment of OA pain has proven to be a difficult chal-
lenge because of the multitude of complex underlying
mechanisms and the fact that different patients show a
varied response to the same therapy. The preferred first
line treatment for OA pain is non-steroidal anti-inflam-
matory drugs; however, the beneficial outcome of these
drugs is limited and some patients fail to achieve any
pain relief at all. Therefore, there is a pressing need to
understand the causes and mechanisms of OA pain so
that more efficacious targets can be identified to help
alleviate these debilitating symptoms. Chronic joint pain
originates in the periphery by the sensitization of pri-
mary afferent nerve fibers innervating the joint leading
to heightened neuronal activity [1-4]. Prolonged bom-
bardment from these primary afferents subsequently
sensitizes spinal and supra spinal neurons leading to the
experience of persistent pathological pain.
Intra-articular injection of monosodium iodoacetate
(MIA) inhibits glyceraldehye-3-phosphate dehydrogenase
activity in chondrocytes, resulting in disruption of glyco-
lysis and eventual cell death [5-8]. The progressive loss
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of chondrocytes results in histological and morphologi-
cal changes to the articular cartilage, closely resembling
those seen in human OA [9]. We have shown previously
that joints contain mechanosensitive nerves [10] which
become sensitized following MIA-induced joint degen-
eration [11,12] leading to chronic joint pain [13].
Voltage- gated sodium channels (VGSCs) are funda-
mental in regulating the excitability of neurons and
overexpression of these channels can produce abnormal
spontaneous firing patterns which underpin chronic
pain [14,15]. There are at least nine different VGSC sub-
types in the nervous system, and each subtype can be
functionally classified as either tetrodotoxin-sensitive or
tetrodotoxin-resistant [16]. Neuronal sodium channel
subtypes including Nav1.3, Nav1.7, Nav1.8, and Nav1.9
have been implicated in the processing of nociceptive
information [17]. The VGSC Nav1.8 is a tetrodotoxin-
resistant sodium channel with a distribution restricted
to primary afferent neurons [18,19] and the majority of
Nav1.8-containing afferents transmit nociceptive signals
to pain processing areas of the spinal cord [20]. Changes
in the expression, trafficking and redistribution of
Nav1.8 following inflammation or nerve injury are
thought to be a major contributor to the sensitization of
afferent nerves and the generation of pain [21]. The
exclusive distribution of this channel on nociceptive
neurons makes it an attractive target for the treatment
of pain. Targeting of the Nav1.8 sodium channel with
genetic deletions and antisense treatment has confirmed
that this channel contributes to normal and pathological
nociception [19,22-24]. A-803467 is a potent and selec-
tive Nav1.8 sodium channel blocker which has been
found to attenuate pain in different rat models of neuro-
pathic and inflammatory pain when given systemically
[25-27]. The present study investigated if local intra-
arterial administration of A-803467 could reduce the
hypersensitivity of nociceptive joint afferents and the
resultant joint pain in the rat MIA model of OA.
Materials and methods
Animals
Experiments were performed on 44 male Wistar rats
(340 to 430 g) which were housed in cages at room
temperature (22°C) under a 12:12 hour light/dark cycle
with free access to water and food. The animal handling
and surgical procedures outlined in this study all
received ethical approval from the University of Calgary
Animal Care Committee and adhered to the Canadian
Council for Animal Care guidelines for the care and use
of experimental animals.
Induction of OA
Forty-four rats were deeply anaesthetised with 2% iso-
flurane in 100% O2 (1 L/minute) until the flexor
withdrawal reflex was abolished. OA was induced by an
injection of 3 mg sodium monoiodoacetate (Tocris
Bioscience, Missouri USA; 50 μl volume) in 0.9% saline
into the joint cavity through the patellar ligament. Ani-
mals were allowed to recover for 14 days which has
consistently been shown to cause severe end-stage OA
in this species [5,7,8].
Surgical preparation for electrophysiological recordings
Following OA development, animals were deeply anaes-
thetized with urethane (25% stock solution; 2 g/kg, i.p.)
and an acceptable depth of anaesthesia was determined
by the absence of the hindpaw withdrawal reflex. Core
body temperature was measured by a rectally inserted
thermometer and maintained at 37°C. The trachea was
cannulated and connected to a Harvard rodent respira-
tory pump to allow artificial ventilation with 100% O2
(stroke volume: 2.5 ml breath frequency: 60 breaths/
min). The left carotid artery was then exposed and can-
nulated with a fine bore catheter (Portex Fine Bore Tub-
ing, 0.5 mm ID, 1.00 mm OD; SIMS Portex Ltd., Kent,
UK) containing heparinized saline (100 units/ml). The
cannula was connected to a pressure transducer to
allow continuous blood pressure measurement as
recorded by a blood pressure monitor (BP-1, World Pre-
cision Instruments, Sarasota, FL, USA). An additional
catheter containing heparinized saline was placed in the
left jugular vein (Portex Fine Bore Tubing, 0.40 mm ID,
0.80 mm OD; SIMS Portex Ltd., Kent, UK) and a single
administration of the muscle relaxant gallamine triethio-
dide (Sigma-Aldrich, Ontario, Canada; 50 mg/kg) was
injected to eliminate neural interference arising from
the hindlimb musculature. The right saphenous artery
was cannulated below the knee joint to permit local
close intra-arterial injection of A-803467 to the knee
joint. A specialized clamp was fixed to the mid-shaft of
the isolated right femur and attached to a stereotaxic
frame to prevent movement of the proximal aspect of
the rat hindlimb. To apply rotation to the knee joint,
the right hindpaw was placed in a shoe-like holder and
the hindlimb rotated to standardized torque levels as
measured by a force transducer and a torque meter
(MVD2510; Hottinger-Baldwin Messtechnik, Darmstadt,
Germany). Finally, a longitudinal skin incision was made
along the medial aspect of the hindlimb and the skin
flaps were fixed to a metal ‘O’ ring to create a pouch
which was filled with warm paraffin oil to prevent tissue
desiccation throughout the experiment. The technique
used for recording afferent activity from articular nerve
fiber from rat knee joints has been described previously
[28]. To prevent input from the foot and ankle region,
the saphenous nerve was transected distally to the knee
joint. The saphenous nerve was then isolated in the
inguinal region and cut centrally to prevent the
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generation of spinally mediated reflexes. The saphenous
nerve stump projecting from the knee was placed on a
small, black Perspex stage. Under a dissecting microscope,
the perineurium was removed and fine neurofilaments
were dissected free from the nerve using fine watchmaker
forceps. The neural elements were then placed over a pla-
tinum electrode to record single afferent fiber activity. To
ensure that recorded fibers originate from the knee joint,
the receptive field of the fibers was identified by the elicita-
tion of a response to gentle probing of the knee joint with
a glass rod with a 1 mm tip. The mechanical threshold of
each recorded joint afferent was determined by a gradual
increase of torque to the joint until the fiber started to eli-
cit action potentials. Non-noxious and noxious outward
movements were then applied to the knee with each
movement lasting ten seconds. Non-noxious movement is
defined here as being within the normal working range of
the joint, while noxious rotation refers to torque occurring
outside the normal range but not severe enough to cause
soft tissue injury. After three movement cycles, identical
test rotations were repeated every two minutes such that
each fiber was subjected to a total of 22 movements. The
conduction velocity of the nerve fibers (C-fibers < 2
meters/second; Aδ-fibers 2-10 meters/second) was deter-
mined by electrical stimulation of the receptive field with
a bipolar silver wire electrode (1-10 V, 0.5 msec pulse
width). The conduction velocity was calculated by dividing
the distance between the receptive field and the electrode
by the latency between the stimulus artefact and the
evoked action potential. Recordings were made before
(control) and after close intra-arterial injection of the Nav
1.8 channel blocker A-803467. The dose of A-803467
administered was 500 ug in 100 ul vehicle (2% dimethyl
sulfoxide (DMSO), 1% cremophor, 0.9% saline). This dose
has previously been shown to be effective in attenuating
evoked pain in inflamed hindpaws [27]. Percentage
changes in nerve firing rate before and after administration
of A-803467 were calculated. Neuronal activity was
recorded by a data acquisition system (CED1401, Cam-
bridge Electronic Design, Cambridge, UK) and stored on a
microcomputer for off-line analysis. The number of action
potentials/movement was determined using Spike 2 soft-
ware (Cambridge Electronic Design, Cambridge, UK).
Behavioral assessment of pain
For measuring joint pain behavior, MIA-treated rats were
regularly handled and gradually habituated to the test
equipment on three consecutive days prior to behavioral
testing. Hindlimb weight bearing was determined using an
incapacitance tester (Linton, Norfolk, UK) consisting of a
dual channel weight averager. The force exerted by each
hindlimb (measured in grams) was averaged over a five
second period. Each data point is the mean of three conse-
cutive readings. For MIA animals, weight distribution was
measured between treated (intra-articular injection of A-
803467 10 mg; 100 μl bolus) and contralateral non-treated
hindlimbs. For secondary allodynia measurements, a von
Frey hair algesiometer (Ugo-Basile, Milan, Italy) was
employed to determine the force required to elicit a with-
drawal response to a tactile mechanical stimulus applied
to the hindpaw. The rat was placed on a metal mesh sur-
face in an enclosed area and allowed to move about freely.
With the animal at rest (that is, in the absence of any
exploratory or grooming behavior) a touch stimulator unit
was oriented under the animal and using an adjustable
angled mirror the stimulating microfilament (0.5 mm dia-
meter) was positioned below the plantar surface of the
paw. Activation of the unit caused the fine metal monofi-
lament to advance with constant speed and touch the paw
in the proximal metatarsal region. The filament exerts a
gradually increasing force to the plantar surface, starting
below the threshold of detection and increasing until the
stimulus becomes painful and the rat withdraws its paw.
The force required to elicit a paw withdrawal reflex is
automatically recorded and measured in grams. A maxi-
mum force of 50 g and a ramp speed of 4.5 g/second were
chosen for all of the algesiometry tests.
Drugs and reagents
Sodium monoiodoacetate and A-803467 were obtained
from Tocris Bioscience (Minneapolis, MN, USA; Bristol,
UK); gallamine triethiodide, DMSO, cremophor and
urethane were obtained from Sigma Aldrich (Oakville,
Ontario, Canada; Poole, UK). A-803467 was dissolved in
vehicle solution (2% DMSO, 1% cremophor, 0.9% saline)
and aliquots of the drug were kept frozen (-20°C) in
Eppendorf vials until required. The pH of all solutions
was determined to exclude acidity as a sensitizing factor
on afferent nerve fibers. All solutions were found to
have a neutral pH (pH 7.4) before injection. Gallamine
triethiodide was made fresh on the day of experimenta-
tion and dissolved in 0.9% saline.
Statistics
All data were normally distributed and expressed as
means ± SEM for ‘n’ observations. Establishment of
joint pain and secondary allodynia after MIA injection
was confirmed using a Student’s t-test. The effect of A-
803467 on nociceptive activity was analyzed by two-way
analysis of variance (ANOVA) with a Bonferroni post
test. All differences were considered statistically signifi-
cant when P was less than 0.05.
Results
Electrophysiological recordings
Between one and three afferent fibers were examined
per animal such that a total of 19 units were recorded
in this study. All fibers responded to noxious stimuli
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while only six units responded in both the normal and
noxious working range. A wash out period of at least 60
minutes was observed between administration of A-
803467 to multiple fibers in the same animal. In case
the firing rate of a recorded afferent did not return to
baseline level after 30 minutes no further afferents were
recorded in that particular animal. The conduction velo-
cities of recorded afferents ranged from 0.57 to 2.87 m/
s. Approximately 20% of the recorded fibers were classi-
fied as Aδ fibers with the remaining fibers being slowly
conducting C-fibers. The mechanical threshold of the
recorded fibers ranged from 5 to 35 mNm The average
firing rate of afferents in the MIA-injected joints during
non-noxious joint rotation was 43 ± 6.21 action poten-
tials/10 s movement (n = 10) and 114 ± 9.95 action
potentials/10 s movement with noxious joint rotation (n
= 16) These firing rates are consistent with previous stu-
dies that showed a significant increase in firing rate in
MIA-treated rats compared to saline injected control
joints [12].
Effect of A-803467 on joint afferent mechanosensitivity
With non-noxious rotation of the MIA-injected rat knee
joint, local administration of A-803467 had no effect on
mechanosensitivity of joint afferents; however, A-803467
reduced the mechanosensitivity during noxious rotation
of the joint. A specimen recording from a typical joint
afferent before and after either vehicle or A-803467
application is shown in Figure 1A and 1B respectively.
The desensitizing effect of A-803467 during noxious
joint rotation was significant at 11 minutes after drug
application and reached a maximum at the 13 minute
time point (mean: -51.45% ± 8.81; % change compared
to control). Compared to vehicle, A-803467 had no sig-
nificant effect on firing rate during non-noxious rotation
(P = 0.49 two-way ANOVA with Bonferroni’s post-test;
n = 6/group (Figure 2A); but significantly reduced the
firing rate during noxious joint rotation (P < 0.0001
two-way ANOVA with Bonferroni ‘s post-test; n = 10 to
12 vehicle group, n = 18 to 19 A-803467 group; Figure
2B). Both, A-δ fibers and C-fibers were equally respon-
sive to A-803467. The vehicle was found to have no sig-
nificant effect on joint mechanosensitivity. Spontaneous
activity was observed in four of the recorded joint affer-
ents. The mean frequency of spontaneous firing before
drug application was 0.53 ± 0.1 Hz and 1 minute after
A-803467 afferent activity was 0.63 ± 0.2 Hz. The lack
of effect of A-803467 on spontaneous activity was con-
sistent across the 15 minute time course perineurium (P
= 0.46 two-way ANOVA; n = 4/group; Figure 3).
Effect of A-803467 on joint pain and secondary allodynia
The induction of OA caused a significant reduction in
the amount of weight being borne on the ipsilateral
hindlimb compared to naïve rats (P < 0.0001; unpaired
Student’s t-test; n = 20 naïve rats, n = 6 OA rats; Figure
4A). While naive rats distribute their body weight evenly
between the two hindlimbs, in the MIA rat the weight
placed on the ipsilateral hindlimb was reduced to about
35% ± 1.46. Intraarticular injection of A-803467 into the
MIA-treated joint reduced the difference in weight bear-
ing significantly such that 43% ± 2.89 of the animal’s
body weight was now placed on the ipsilateral hindlimb.
This improvement in weight distribution was significant
compared to vehicle treated animals (P < 0.0001; two-
way ANOVA with Bonferroni ‘s post test; n = 10; Figure
4A) indicating that A-803467 reduced pain in MIA
joints. Injection of the vehicle by itself had no effect on
weight distribution.
Paw withdrawal threshold to mechanical stimuli in
naïve animals (mean: 39.7 g ± 1.69), was significantly
reduced in MIA arthritic rats (mean: 26.80 g ± 1.27
indicating the presence of secondary allodynia (P =
0.0002; unpaired Student’s t test; n = 10 naïve rats, n =
6 OA rats; Figure 4B). Intra-articular A-803467 injection
Figure 1 Effect of Nav1.8 ion channel blockade on joint
nociception. Figure shows a typical single unit recording of an
unmyelinated C-fiber (conduction velocity: 1.38 m/sec) in response
to normal and noxious rotation of MIA arthritic knee joints.
Recording shows nerve firing activity before (A) and after (B) close
intra-arterial injection of A-803467. Coincidental torque levels are
displayed below each nerve recording. Movement-evoked afferent
firing rate was reduced by local administration of the Nav1.8 ion
channel blocker.
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Figure 2 Time course of effect of A-803467 on joint mechanosensitivity. Local application of A-803467 had no effect on joint afferent firing
rate during non noxious rotation of the joint (A) n = 6/group, but significantly reduced nociceptor activity during noxious joint rotation (B). 2-
way ANOVA; n = 10 to12 vehicle group, n = 18 to 19 A-803467 group. Values are means ± SEM.
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significantly reduced this MIA-induced mechanical
hypersensitivity (mean: 32.25 g ± 1.84) compared to
vehicle treated animals (mean: 22.83 g ± 2.62; P <
0.0001, two-way ANOVA with Bonferroni’s post test; n
= 10; Figure 4B.
Discussion
Management of osteoarthritis pain remains a huge chal-
lenge in the clinic with millions of arthritis patients liv-
ing with chronic disability. Limitations to current
pharmacological treatment strategies include a lack of
therapeutic efficacy and potentially hazardous side-
effects. Therefore, there is a pressing need to understand
the underlying mechanisms that evoke OA pain and to
develop new, more effective analgesics. One intuitive
approach would be to attenuate pathological OA-
induced pain by selectively blocking joint nociceptors
while preserving other desirable physiological functions
of the nerve. Intra-articular injection of non-selective
sodium channel blockers has been shown to be effective
for the treatment of OA pain [29] while intravenous
administration of these agents can produce long lasting
pain relief in both animal models [30] and in patients
with intractable neuropathic pain [31]. The clear disad-
vantages of using non-selective sodium channel blockers
locally are complete loss of sensation and disruption of
normal physiological functions such as proprioception
and neurovasoregulation. Systemic use of such blockers
can lead to cardiotoxicity, sedation and cognitive impair-
ment [32]. Targeting sodium channels which are located
exclusively on nociceptive afferents could reduce these
undesirable side effects. The novel small molecule A-
803467 selectively blocks the Nav1.8 sodium channel in
vitro and in vivo [25]. The agent has been shown to
inhibit inward currents in cultured rat dorsal root gang-
lia cells and Nav1.8 expressing HEK cells (IC50 = 8
nM). A-803467 was also found to reduce mechanically-
evoked firing of dorsal horn wide dynamic neurons as
well as mechanical allodynia in animal models of inflam-
mation and neuropathic pain over the dose range 10 to
100 mg/kg. In this study it was found that local admin-
istration of A-803467 significantly reduced OA joint
mechanosensitivity during noxious but not during non-
noxious rotation of the joint. These data confirm that
blocking the Nav 1.8 channel attenuates joint mechano-
nociception in the MIA model of joint degeneration.
The fact that the reduction in mechanosensitivity was
limited to noxious joint rotation confirms that Nav1.8
plays a major role in transmitting strong noxious signals
but does not affect physiological mechanosensitivity dur-
ing normal, non-noxious rotation of the joint.
Approximately 50% of C-fibers and 10% of A-δ fibers
in naive rats express Nav1.8 channels [33] and this pro-
portion increases in painful conditions [21,34]. In
Figure 3 Effect of A-803467 on joint afferent spontaneous activity. Compared to vehicle, local injection of A-803467 had no effect on nerve
spontaneous activity (n = 4/group). Values are means ± SEM.
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Figure 4 Pain behavioral responses to treatment with A-803467. In (A), MIA causes a profound shift in hindlimb weight distribution onto
the unaffected hindlimb. Following A-803467 treatment body weight was re-distributed onto the MIA-treated joint reflecting an analgesic effect.
In (B), hindpaw withdrawal thresholds were measured in response to an intra-articular injection of A-803467. The force required to elicit hindpaw
withdrawal following A-803467 was significantly reduced compared to vehicle-treated animals, confirming a reduction in MIA induced secondary
allodynia. Values are means ± SEM.
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addition, a dynamic redistribution of Nav1.8 channels
from dorsal root ganglia somata to the axons has been
observed so that more Nav1.8 channels are expressed
on C-fibers and A-δ fibers in rat digital nerves after
neuropathic injury [35]. In this study, the firing rate in
about 75% of all recorded afferents was substantially
reduced during noxious rotation after A-803467 admin-
istration. The relatively high percentage of responsive
fibers to A-803467 in this study could be explained by
similar channel reorganization and up-regulation in
response to MIA induced joint pathology. Systemic
administration of A-803467 has been shown to reduce
pain significantly in several models of neuropathic and
inflammatory pain [25-27] while preserving motor func-
tion as assessed by spontaneous exploratory behavior,
and motor coordination as assessed by the rotarod and
edge test assays [25]. In this study, an intra-articular
injection of A-803467 significantly reduced hindlimb
incapacitance and secondary allodynia in MIA-treated
rats. This observation corroborates the electrophysiolo-
gical data which signified an anti-nociceptive effect of
the channel blocker in diseased joints. The inhibitory
effect of intra-articular A-803467 on hindlimb incapaci-
tance confirms that joint Nav1.8 channels are involved
in OA pain and that peripheral modulation of these
channels has analgesic potential. The ability of intra-
articular A-803467 to reduce secondary allodynia in this
study is also of importance as it suggests that the
referred pain associated with OA can be moderated by
blocking Nav1.8 channels in the knee.
Although the evidence presented here highlights the
involvement of peripheral Nav1.8 channels in producing
OA pain, Nav1.8 channels present on the central term-
inals of primary afferent nerves also need to be consid-
ered. It has recently been demonstrated that A-803467
has good penetration into the central nervous system
where it produces a more robust antinociception in neu-
ropathic pain models than a peripherally acting non-
selective sodium channel blocker [36]. This ability of A-
803467 to suppress spinal dorsal horn neuronal excit-
ability and to reduce allodynia effectively after nerve
injury provides further evidence that inhibition of
Nav1.8 channels on peripheral nerves, with synaptic
connections in the spinal cord, is an important site of
nociceptive sensory processing [37] and could be neces-
sary to achieve more pronounced and longer lasting
analgesia.
The present investigation also found that A-803467
had no significant effect on spontaneous nerve activity
in MIA-treated joints. The reason for the lack of effect
of peripheral A-803467 administration on MIA-induced
spontaneous activity could be that articular Nav1.8
channels are only activated by external physical stimuli
and are unaffected by the sensitizing effect of algogenic
agents present in the diseased joint. The central term-
inal of the primary afferent neuron, however, could still
be a useful target for reducing spontaneous activity and
could therefore play a role in the reduction of OA pain
at rest. This hypothesis is supported by studies showing
that intrathecal administration of A-803467 significantly
reduced evoked and spontaneous firing of wide dynamic
range neurons [25] whereas local intra-plantar applica-
tion only reduced evoked but not spontaneous nerve fir-
ing [27]. Since spontaneous activity is necessary for the
perception of chronic, on-going pain in MIA joints [11],
intrathecal A-803467 may be required to address the
problem of pain at rest in OA patients.
In conclusion, this study shows for the first time that
the Nav1.8 channel is involved in mediating nociception
and pain in a rat model of OA. We propose that target-
ing Nav1.8 channels could be a promising approach to
reduce nociceptor sensitivity and consequently pain per-
ception in OA while avoiding the undesirable side-
effects of non-selective sodium channel blockers.
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